Senhwa Biosciences Overview

  • Founded
  • 2012
  • Status
  • Public
  • Employees
  • 16
  • Stock Symbol
  • 6492
Stock Symbol
  • Share Price
  • $3.20
  • (As of Thursday Closing)

Senhwa Biosciences General Information


Senhwa Biosciences Inc primarily engaged in the development of new drugs and special pharmaceutical ingredients focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), Silmitasertib (CX-4945), and Silmitasertib (for Moderate Covid-19). All of its revenue comes from Taiwan.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Primary Office
  • 10th Floor, Number 225, Section 3, Peihsin Road
  • Hsintien District
  • New Taipei City, 231-43
  • Taiwan
+886 02 0000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Senhwa Biosciences Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.20 $3.23 $2.98 - $8.41 $287M 89.7M 936K -$0.13

Senhwa Biosciences Financials Summary

In Thousands,
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 393,262 637,683 131,177 132,140
Revenue 21 21 10 24
EBITDA (11,565) (11,925) (12,537) (12,440)
Net Income (11,654) (12,056) (12,667) (12,459)
Total Assets 77,970 85,870 28,706 40,738
Total Debt 600 427 252 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Senhwa Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Senhwa Biosciences‘s full profile, request access.

Request a free trial

Senhwa Biosciences Patents

Senhwa Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210308110-A1 Antiviral compounds and method for treating rna viral infection, particularly covid-19 Pending 30-Mar-2020 00000000000
US-20210308137-A1 Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis b and hepatitis d Pending 30-Mar-2020 00000000000
US-20210046082-A1 Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use Pending 14-Aug-2019 0000000000
US-20210046071-A1 Tetracyclic compounds and their salts, compositions, and methods for their use Pending 14-Aug-2019 0000000000
EP-3866804-A1 Combinations for immune-modulation in cancer treatment Pending 19-Oct-2018 A61P35/00

Senhwa Biosciences Executive Team (5)

Name Title Board Seat Contact Info
Sarah Chang Chief Financial Officer, Director & Head, Finance and Administration
Hshiou-ting Liu Ph.D Vice President of Chemistry and Pharmaceutical Operations
You’re viewing 2 of 5 executive team members. Get the full list »

Senhwa Biosciences Board Members (3)

Name Representing Role Since
Benny Hu Senhwa Biosciences Chairman & Board Member 000 0000
Tai-Sen Soong Ph.D Senhwa Biosciences Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Senhwa Biosciences Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial